Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

NCT02430493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1066

Last updated 2018-03-14

No results posted yet for this study

Summary

The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined in 8.1 and other serious adverse events (SAEs) during 1-year follow up in Chinese acute coronary syndrome (ACS) patients.

Conditions

  • Acute Coronary Syndrome (ACS)

Sponsors & Collaborators

Principal Investigators

  • Changsheng Ma · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-28
Primary Completion
2017-03-29
Completion
2017-03-29

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430493 on ClinicalTrials.gov